A Phase 1 interventional study of maraviroc and Trofile Assay and HIV RNA quantification assay in HIV Infections, sponsored by ViiV Healthcare. Terminated at 10 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.
Among the 44 studies testing maraviroc in HIV Infections, this one is the 32nd largest by enrollment, is one of 5 that started in 2007, is one of 7 in phase 1, and was the 4th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →
Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 9 · Phase 4 15
First in 2002; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 36 across the 44 interventional studies. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 189th largest by enrollment of the 210 interventional ones that give a count, is one of 9 that started in 2007, is one of 83 in phase 1, and was the 119th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing maraviroc in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this pilot study is to determine whether there is a correlation between viral load reduction (at Day 4, 7 or 14) following a short course (14 days) of Maraviroc added to a failing regimen, and the R5 result of the TrofileTM assay at screening.
The study A4001060 has been discontinued on April 22, 2008. A review of the poor rate of enrollment has projected difficulties in completing the study in a timely manner, despite the best efforts by the sponsor and the sites. Given the difficulties encountered in this pilot study and the need to conduct an even larger confirmatory study, the decision to discontinue the study has therefore been made. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: maraviroc · Procedure: Trofile Assay and HIV RNA quantification assay
Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
Trofile Assay and HIV RNA quantification assay
Change From Baseline in Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) With R5 & Non-R5 Tropism Results From the Trofile(tm) Assay
Spearman's correlation coefficient to assess percentage of participants achieving HIV-1 RNA with tropism
Time frame: Baseline, Day 4, 7, 14
Subjects Achieving HIV-1 RNA <400 Copies/mL
Number of Subjects Achieving HIV-1 RNA \<400 Copies/mL at each time point
Time frame: Days 4, 7, 14, 28, and Weeks 8, 12, 18, and 24
Subjects Achieving HIV-1 RNA <50 Copies/mL
Number of Subjects Achieving HIV-1 RNA \<50 Copies/mL at each time point
Time frame: Days 4, 7, 14, 28, and Weeks 8, 12, 18, and 24
Subjects With Virologic Failure
For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.
Time frame: Baseline up to Week 24
Time to Virologic Failure
For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.
Time frame: Baseline up to Week 24
Change in Lymphocyte Subset CD4 From Baseline
Calculated average of CD4 at Day 7, 14, 28 and Week 24 minus CD4 at Day 1
Time frame: Day 1 (Baseline), Day 7, 14, 28 and Weeks 24
Change in Lymphocyte Subset CD8 From Day 1
Calculated average of CD8 at Day 7, 14, 28 and Week 24 minus CD8 at Day 1
Time frame: Day 1(Baseline), Day 7, 14, 28 and Weeks 24
Change in Lymphocyte Subsets; CD4 and CD8 From Screening.
Calculated avergae of {CD4 or CD8 at Day 1 - CD4 or CD8 at Screening}
Time frame: Screening (Day -14 to 0), Day 1.
Change in Detectable Tropism From Screening
Number of subjects who switch their tropism status from screening to Baseline
Time frame: Screening (Day -21 to 0), Baseline.
Change in Detectable Tropism From Baseline
Number of subjects who switch their tropism status from Baseline to Days 7, 14, and Week 24/End of Study(EOS)/Discontinuation
Time frame: Baseline, Day 15 and Week 24/End of Study/Discontinuation
Change in Detectable Resistance (Genotype) and Susceptibility (Phenotype) to Drugs in the Regimen From Screening
Change in detectable resistance (genotype) and susceptibility (phenotype) to drugs in the regimen from Screening
Time frame: Screening (Day -21), Baseline (Day 0), Day 14 (after addition of MVC to a failing regimen), Week 24, and time of Virologic Failure.
Number of Subjects With Susceptibility to Maraviroc
Phenotypic susceptibility to maraviroc
Time frame: Screening (Day -21 to 0), Day 14, Week 24
Change in Gene Sequence in Gp-160, and the V3 Loop From Screening Visit (Day -21 to 0) to Day 14, Time of Virologic Failure (See Section 6.5.1) and Week 24
Change in gene sequence in gp-160, and the V3 loop from Screening visit (Day -21 to 0) to Day 14, time of virologic failure (See Section 6.5.1) and Week 24
Time frame: Screening (Day -21 to 0), Day 14, time of virologic failure, and Week 24
Correlation of Mutations in gp160 and the V3 Loop and Decreased Susceptibility to Maraviroc
Time frame: Screening (Day -21 to 0), Day 14, time of virologic failure, Week 24
| Milestone | CCR5-Tropic HIV-1 | Non-CCR5-Tropic HIV-1 |
|---|---|---|
| Started | 9 | 7 |
| Completed | 8 | 5 |
| Not completed | 1 | 2 |
| Withdrew: Protocol violation | 1 | 2 |
Number of Subjects Achieving HIV-1 RNA \<400 Copies/mL at each time point
No measurements were reported for this outcome.
Number of Subjects Achieving HIV-1 RNA \<50 Copies/mL at each time point
No measurements were reported for this outcome.
For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.
No measurements were reported for this outcome.
For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.
No measurements were reported for this outcome.
Calculated average of CD4 at Day 7, 14, 28 and Week 24 minus CD4 at Day 1
No measurements were reported for this outcome.
Spearman's correlation coefficient to assess percentage of participants achieving HIV-1 RNA with tropism
No measurements were reported for this outcome.
Calculated average of CD8 at Day 7, 14, 28 and Week 24 minus CD8 at Day 1
No measurements were reported for this outcome.
Calculated avergae of {CD4 or CD8 at Day 1 - CD4 or CD8 at Screening}
No measurements were reported for this outcome.
Number of subjects who switch their tropism status from screening to Baseline
No measurements were reported for this outcome.
Number of subjects who switch their tropism status from Baseline to Days 7, 14, and Week 24/End of Study(EOS)/Discontinuation
No measurements were reported for this outcome.
Change in detectable resistance (genotype) and susceptibility (phenotype) to drugs in the regimen from Screening
No measurements were reported for this outcome.
Phenotypic susceptibility to maraviroc
No measurements were reported for this outcome.
Change in gene sequence in gp-160, and the V3 loop from Screening visit (Day -21 to 0) to Day 14, time of virologic failure (See Section 6.5.1) and Week 24
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CCR5-Tropic HIV-1 | — | 4/9 (44.4%) | 9/9 (100%) |
| Non-CCR5-Tropic HIV-1 | — | 0/7 (0%) | 4/7 (57.1%) |
| Event | CCR5-Tropic HIV-1 | Non-CCR5-Tropic HIV-1 |
|---|---|---|
| Myocardial InfarctionCardiac disorders | 1/9 | 0/7 |
| OrchitisInfections and infestations | 1/9 | 0/7 |
| PneumoniaInfections and infestations | 1/9 | 0/7 |
| Testicular neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/9 | 0/7 |
| HeadacheNervous system disorders | 1/9 | 0/7 |
| SyncopeNervous system disorders | 1/9 | 0/7 |
| Testicular swellingReproductive system and breast disorders | 1/9 | 0/7 |
| Event | CCR5-Tropic HIV-1 | Non-CCR5-Tropic HIV-1 |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 3/9 | 0/7 |
| Neuropathy peripheralNervous system disorders | 2/9 | 0/7 |
| RashSkin and subcutaneous tissue disorders | 2/9 | 0/7 |
| HeadacheNervous system disorders | 2/9 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 1/7 |
| VomitingGastrointestinal disorders | 1/9 | 1/7 |
| DizzinessNervous system disorders | 1/9 | 1/7 |
| DyspepsiaGastrointestinal disorders | 0/9 | 1/7 |
| NauseaGastrointestinal disorders | 0/9 | 1/7 |
| Otitis ExternaInfections and infestations | 0/9 | 1/7 |
| Age, Continuous(years) | CCR5-Tropic HIV-1 | Non-CCR5-Tropic HIV-1 | Total |
|---|---|---|---|
| Mean | 46.3 ± 4.9 | 41.0 ± 4.8 | 44.0 ± 5.4 |
| Sex: Female, Male(Participants) | CCR5-Tropic HIV-1 | Non-CCR5-Tropic HIV-1 | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 8 | 6 | 14 |
The record gives a start of Jul 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc